Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?
Aakash Desai, Vinay Prasad
https://pubmed.ncbi.nlm.nih.gov/33904047Actively Recruiting
Phase Not Applicable
Age: 0 - 80Years
All Genders
Healthy Volunteers
ID07384897
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Led by Université Catholique de Louvain · Updated on 2026-02-03
425
Participants Needed
1
Research Sites
63 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of immune system cells in lung diseases, including lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The study aims to understand how these immune cells can both protect the body and sometimes contribute to cancer growth or ongoing lung inflammation. The research also seeks to explore why some patients do not respond or develop resistance to immunotherapy treatments, with the goal of improving personalized care in the future. Participants include groups such as patients with precancerous lung lesions, those diagnosed with lung cancer at any stage, individuals with chronic inflammatory lung diseases like sarcoidosis or COPD, healthy volunteers without lung disease, children and adolescents with chronic granulomatous disease, and adults undergoing orthopedic surgery who will provide bone marrow samples. The study involves collecting biological samples like peripheral blood, tumor tissue, lymph nodes, and bone marrow when available, to analyze immune cell types and their functions. No experimental treatments are given; all medical care is independent of study participation. During the study, participants provide biological samples for immune profiling to help researchers study immune mechanisms related to disease progression and treatment responses. The primary outcome measured is progression-free survival over approximately seven years. Study participation includes regular monitoring without altering usual medical care. The study runs from February 2025 to February 2032, with a maximum participant age of 80 years.
CONDITIONS
Brief Title
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Who Can Participate
Age: 0 - 80Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Diagnosis of lung cancer
- Presence of precancerous lung lesions
- Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment
- Control group: individuals without known lung disease
- Children and adolescents weighing 210 kg with genetically confirmed chronic granulomatous disease (CGD)
- Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
You will not qualify if you...
- Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
- Acute infection at the time of inclusion
- Refusal or inability to provide informed consent (or assent, when applicable)
- Chronic inflammatory lung disease currently treated with immunosuppressive therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Sample Collection
Duration - Throughout the entire study, approximately during 7 years
Participants provide biological samples including peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue, lymph node, or bone marrow for immune profiling and translational research. No experimental treatments are given. Samples help study immune mechanisms involved in lung cancer, sarcoidosis, COPD, and other conditions.
Periodic sample collections depending on clinical care and study schedule
Long-term Monitoring
Duration - Up to 7 years
Participants are observed over time to monitor disease progression and treatment response based on collected samples and clinical data. This monitoring supports research on immune cell populations and their role in lung disease and cancer.
Follow-up visits as per clinical care and study protocol
Trial Site Locations
Total: 1 location
1
Cliniques universitaires saint Luc
Brussels, Belgium, 1200
Actively Recruiting
Loading map...
Research Team
F
Frank Aboubakar Nana, MD; PhD
K
Kim Henquin, Study nurse
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
6
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Alyson Haslam, Vinay Prasad
https://pubmed.ncbi.nlm.nih.gov/31050774Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation.
Nicolas Delhez, Frank Aboubakar Nana, Camille Houbion...
https://pubmed.ncbi.nlm.nih.gov/39824555How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions.
Annika M Bruger, Anca Dorhoi, Gunes Esendagli...
https://pubmed.ncbi.nlm.nih.gov/29785656Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype.
Christophe Vanhaver, Frank Aboubakar Nana, Nicolas Delhez...
https://pubmed.ncbi.nlm.nih.gov/37931958